About Us

Our Mission

We believe in the power of innovative medicines to improve human lives by eliminating sensory limitations. Through gene therapy solutions, we aim to initially address the underlying genetic causes of hearing impairment to enhance, or even restore natural communication.
  • Targeted micro-dose delivery of gene therapies, initially focused on hearing loss
  • Scientific discovery by experts in inner ear biology at Harvard Medical School/MassGeneral Hospital
  • Proprietary capsid and gene regulatory elements
  • Proof-of-concept in genetic hearing disorder mouse model, NHP biodistribution studies 
  • Leadership and scientific advisors with deep experience in auditory neuroscience, inner ear biology, gene therapy, clinical development and business operations
  • Begin IND-enabling studies in 1H 2024
  • Series A with top-tier investors ARCH Venture Partners and B-Flexion, a Bertarelli Family investment firm

Meet the Team

Leadership
Scientific Advisors
President & CEO
Jodi
Cook, Ph.D.
Chief Development Officer
Shawn
Harriman, Ph.D.
Head of Technical Operations
Anjil
Giri, Ph.D.
Co-Founder
Nilay
Thakar, Ph.D.
Chair of the Board
Steve
Gillis, Ph.D.
Board Member
Giampiero
De Luca, Ph.D.
Co-Founder
David
P. Corey, Ph.D.
40+ years studying inner ear biology; 30 years HHMI
Co-Founder
Casey
Maguire, Ph.D.
20+ years engineering vectors/gene therapies
René
Gifford, Ph.D., CCC-A
25+ years audiology/hearing science; 20 years NIH-funded research
Gregory
Robinson, Ph.D.
30+ years of drug development and gene therapy experience

Stay In

The Know

Blank Form (#3)